PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

A. Tedeschi; M.A. Dimopoulos; J. Trotman; R. García‐Sanz; D. Macdonald; B. Mahe; C. Herbaux; L.T. Heffner; C.S. Tam; M. Varettoni; M.L. Palomba; J.V. Matous; C. Shustik; E. Kastritis; S.P. Treon; J. Li; E.G. Poulsen; B. Hauns; C. Buske; V. Leblond

doi:10.1002/HON.47_2630

PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

A. Tedeschi
, M.A. Dimopoulos
, J. Trotman
, R. García‐Sanz
, D. Macdonald
, B. Mahe
, C. Herbaux
, L.T. Heffner
, C.S. Tam
, M. Varettoni
, M.L. Palomba
, J.V. Matous
, C. Shustik
, E. Kastritis
, S.P. Treon
, J. Li
, E.G. Poulsen
, B. Hauns
, C. Buske
, V. Leblond

Department of Hematology ASST Grande Ospedale Metropolitano Niguarda Milan Italy
National and Kapodistrian University of Athens
University of Sydney
Hematology Hospital Universitario de Salamanca Salamanca Spain
University of Ottawa
Hematology Centre Hospitalier Universitaire de Nantes Nantes France
Institute of Hematolog‐Tranfusion Centre Hospitalier Régional Universitaire de Lille Lille France
Emory University
Peter MacCallum Cancer Centre
Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy
Memorial Sloan-Kettering Cancer Center
Blood Cancer Colorado Blood Cancer Institute Denver CO United States
McGill University Health Centre
Harvard University
Biostatistics Pharmacyclics LLC, an AbbVie Company Sunnyvale CA United States
Regulatory Affairs Pharmacyclics LLC, an AbbVie Company Sunnyvale CA United States
Clinical Science Pharmacyclics LLC, an AbbVie Company Sunnyvale CA United States
Department of Internal Medicine III Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm Ulm Germany
University of Paris

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Hematological Oncology
Volume	37
DOIs	https://doi.org/10.1002/HON.47_2630
State	Published - Jun 12 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1002/HON.47_2630License: Unspecified

Cite this

Tedeschi, A., Dimopoulos, M. A., Trotman, J., García‐Sanz, R., Macdonald, D., Mahe, B., Herbaux, C., Heffner, L. T., Tam, C. S., Varettoni, M., Palomba, M. L., Matous, J. V., Shustik, C., Kastritis, E., Treon, S. P., Li, J., Poulsen, E. G., Hauns, B., Buske, C., & Leblond, V. (2019). PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY. Hematological Oncology, 37. https://doi.org/10.1002/HON.47_2630

Tedeschi, A, Dimopoulos, MA, Trotman, J, García‐Sanz, R, Macdonald, D, Mahe, B, Herbaux, C, Heffner, LT, Tam, CS, Varettoni, M, Palomba, ML, Matous, JV, Shustik, C, Kastritis, E, Treon, SP, Li, J, Poulsen, EG, Hauns, B, Buske, C & Leblond, V 2019, 'PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY', Hematological Oncology, vol. 37. https://doi.org/10.1002/HON.47_2630

@article{79ca8b4a67804c4ba5aa908546fe9ec1,

title = "PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTR{\"O}M MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY",

author = "A. Tedeschi and M.A. Dimopoulos and J. Trotman and R. Garc{\'i}a‐Sanz and D. Macdonald and B. Mahe and C. Herbaux and L.T. Heffner and C.S. Tam and M. Varettoni and M.L. Palomba and J.V. Matous and C. Shustik and E. Kastritis and S.P. Treon and J. Li and E.G. Poulsen and B. Hauns and C. Buske and V. Leblond",

note = "Introduction: Anemia and fatigue are known to impair quality of life in patients with WM. Ibrutinib, a first-in-class, once-daily inhibitor of BTK, is approved in the EU for the treatment of WM after ≥1 prior therapy or as first-line therapy in patients unsuitable for chemoimmunotherapy.",

year = "2019",

month = jun,

day = "12",

doi = "10.1002/HON.47\_2630",

language = "American English",

volume = "37",

journal = "Hematological Oncology",

issn = "1099-1069",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

AU - Tedeschi, A.

AU - Dimopoulos, M.A.

AU - Trotman, J.

AU - García‐Sanz, R.

AU - Macdonald, D.

AU - Mahe, B.

AU - Herbaux, C.

AU - Heffner, L.T.

AU - Tam, C.S.

AU - Varettoni, M.

AU - Palomba, M.L.

AU - Matous, J.V.

AU - Shustik, C.

AU - Kastritis, E.

AU - Treon, S.P.

AU - Li, J.

AU - Poulsen, E.G.

AU - Hauns, B.

AU - Buske, C.

AU - Leblond, V.

N1 - Introduction: Anemia and fatigue are known to impair quality of life in patients with WM. Ibrutinib, a first-in-class, once-daily inhibitor of BTK, is approved in the EU for the treatment of WM after ≥1 prior therapy or as first-line therapy in patients unsuitable for chemoimmunotherapy.

PY - 2019/6/12

Y1 - 2019/6/12

UR - https://onlinelibrary.wiley.com/doi/full/10.1002/hon.47_2630

U2 - 10.1002/HON.47_2630

DO - 10.1002/HON.47_2630

M3 - Article

SN - 1099-1069

VL - 37

JO - Hematological Oncology

JF - Hematological Oncology

ER -

PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

Disciplines

Access to Document

Other files and links

Cite this